Telix Pharmaceuticals

Telix Pharmaceuticals

Yahoo Finance • yesterday

Telix Pharmaceuticals Stock Leads 3 Fast Growing Insider Owned Shares

Global demand tied to AI related investment is shaping trade and capital flows, and that is putting growth companies with clear earnings ambitions back in focus. Investors are searching for businesses that can convert this demand into real... Full story

Yahoo Finance • last month

TLX591-Tx ProstACT SELECT Study Published in Cancers Journal

Peer-reviewed publication of ProstACT SELECT1 results confirm the utility of 68Ga (gallium)-PSMA-PET imaging to select patients for TLX591-Tx therapy using a theranostic approach2.Consistent with previously reported results3, the publicati... Full story

Yahoo Finance • last month

Telix Pharmaceuticals Q2 Revenue Climbs Boosted By Precision Medicine Business

(RTTNews) - Telix Pharmaceuticals Limited (TLX), a radiopharmaceutical company, reported a rise in revenue for the second quarter, helped by the increased revenue from the precision medicine business. For the second quarter of fiscal 2026... Full story

Yahoo Finance • last month

Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer

First patient dosed in Phase 3 LUTEON1 trial evaluating TLX250-Tx in relapsed or recurrent clear cell renal cell carcinoma (ccRCC).LUTEON is the first Phase 3 study of a CAIX2-targeted radiopharmaceutical therapy in ccRCC. MELBOURNE (Aust... Full story

Yahoo Finance • 2 months ago

FDA Alignment to Advance ProstACT Global Phase 3 Trial

FDA and Telix align on advancement into Part 2 of the ProstACT Global Phase 3 study in the United States.FDA agrees with the clinical protocol and proposed statistical framework across three standard-of-care combination cohorts.Part 2 (ran... Full story

Yahoo Finance • 3 months ago

ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026

Telix’s first-in-class lutetium radio antibody-drug conjugate (rADC) candidate, TLX591-Tx, demonstrates acceptable tolerability across all standard-of-care (SoC) combination cohorts, with no new safety signals.Findings support feasibility... Full story

Yahoo Finance • 4 months ago

EDAP | Focal One and Telix Announce Collaboration Focused on Robotic HIFU and Theranostics in Prostate Cancer

, May 14, 2026 (GLOBE NEWSWIRE) -- AUSTIN, Texas – May 14, 2026 – EDAP TMS S.A. (Nasdaq: EDAP) today announced that it has entered into a letter of intent with Telix Pharmaceuticals Limited (“Telix”) to explore joint clinical research ac... Full story

Yahoo Finance • 4 months ago

OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer

TLX597-Tx is a PSMA1-targeting small molecule radioligand therapy (RLT) candidate, designed to improve quality-of-life and efficacy in earlier-stage prostate cancer.OPTIMAL-PSMA2 initial dosimetry data demonstrate low salivary gland and ki... Full story

Yahoo Finance • 4 months ago

Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma

MELBOURNE, Australia and INDIANAPOLIS, April 15, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient has been dosed with TLX101-Tx (¹³¹I-iodofalan) in Telix’s piv... Full story

Yahoo Finance • 5 months ago

Telix And Regeneron Partner To Advance Next-Generation Radiopharmaceutical Therapies

(RTTNews) - Telix Pharmaceuticals Limited (TLX, TLX.AX) and Regeneron Pharmaceuticals, Inc. (REGN) have announced a collaboration to jointly develop and commercialize next-generation radiopharmaceutical therapies. This partnership brings t... Full story

Yahoo Finance • 5 months ago

Telix and Regeneron Announce Strategic Radiopharma Collaboration

Telix and Regeneron to co-develop and co-commercialize next-generation radiopharmaceutical therapies in a 50/50 cost and profit-sharing model. Collaboration combines Telix's expertise in radiopharmaceutical development and manufacturing wi... Full story

Yahoo Finance • 5 months ago

FDA Accepts NDA for TLX101-Px (Pixclara®)

MELBOURNE, Australia and INDIANAPOLIS, April 10, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the Co... Full story

Yahoo Finance • 5 months ago

Telix Strengthens Board with Additional Director Appointments

MELBOURNE, Australia and INDIANAPOLIS, April 09, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces two additional Non-Executive Director (NED) appointments, effective May 11, 20261, a... Full story

Yahoo Finance • 5 months ago

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday Ahead of Trump's Hormuz Reopening Deadline

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.6% and the actively tr PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 5 months ago

Top European Dividend Stocks To Consider For Your Portfolio

As European markets experience a positive shift, with the STOXX Europe 600 Index rising by 3.92% amid hopes for a shorter Middle East conflict, investors are increasingly looking at dividend stocks as a stable source of income amidst energ... Full story

Yahoo Finance • 5 months ago

Telix Pharma Reports 24% Revenue Growth In Q1; Stock Up

(RTTNews) - Telix Pharmaceuticals Limited (TLX), a commercial-stage company, reported first-quarter results on Monday, reflecting 24% revenue growth compared to the prior year. In addition, the firm reaffirmed its 2026 revenue guidance. F... Full story

Yahoo Finance • 5 months ago

Telix Appoints David Gill as Non-Executive Director

MELBOURNE, Australia and INDIANAPOLIS, April 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces the appointment of David Gill as a Non-Executive Director (NED), as part of Board ex... Full story

Yahoo Finance • 5 months ago

Telix selects IBA Cyclone® KIUBE to support manufacturing expansion in the U.S.

Louvain-la-Neuve, Belgium– March 20, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions, today announced it ha... Full story

Yahoo Finance • 5 months ago

Telix choisit le Cyclone® KIUBE d’IBA pour étendre ses capacités de production aux États‑Unis

Louvain‑la‑Neuve, Belgique, le 20 mars 2026 — IBA (Ion Beam Applications S.A., EURONEXT), leader mondial des technologies d’accélérateurs de particules et premier fournisseur mondial de solutions de production de radiopharmaceutiques, anno... Full story

Yahoo Finance • 5 months ago

Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging Candidate

MELBOURNE, Australia and INDIANAPOLIS, March 16, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces the resubmission of a New Drug Application (NDA) to the United States (U.S.) Food an... Full story